Drug intelligence / Profile preview

Fibrostop

Development stage
Phase 1
Lead developer
Birch BioMed
Modality
Small Molecules
Administration
Topical
01

Overview

Fibrostop refers to a pipeline of topical therapeutic candidates, including Fibrostop 1 (FS1) and Fibrostop 2 (FS2), designed to treat dermal fibroproliferative disorders such as hypertrophic scars and keloids. Fibrostop 1 is a formulation of the amino acid metabolite kynurenine, while Fibrostop 2 is based on kynurenic acid. These compounds are endogenous catabolites of tryptophan that act by stimulating the expression of Matrix Metalloproteinase-1 (MMP-1) and Matrix Metalloproteinase-3 (MMP-3) in dermal fibroblasts. This induction of MMPs facilitates the degradation of excess collagen deposits, which are the primary cause of raised, itchy, and red pathological scarring. Developed by researchers at the University of British Columbia, the FS2 formulation has been evaluated in Phase 1 clinical trials for safety and tolerability in healthy volunteers.

Brand names
Fibrostop 1Fibrostop1Fibrostop-1Fibrostop 2Fibrostop2Fibrostop-2
Other names
KynurenineKynurenic acid
02

Targets

MMP1 (Matrix metalloproteinase-1)MMP3 (Matrix metalloproteinase-3)

Beyond the preview

Go deeper on Fibrostop.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fibrostop.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call